Burixafor (TG-0054) vs Motixafortide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: CXCR4 · full Multiple Myeloma pipeline

Burixafor (TG-0054)

Developed by GPCR Therapeutics, Inc. and partners

Phase 2 in Multiple Myelomasmall molecule
Weak signal

NCT01018979 · Phase 2 · completed

Although this study assigned patients to two dose levels, it had no placebo or active-comparator arm and was fully open-label (no masking), so there was no control against which to judge the drug's effect. Only 19 patients were treated, and most (13 of 19) dropped out before completing collection because their stem cell counts never rose high enough, leaving just 4 and 3 patients per dose group who even underwent apheresis for the primary mobilization-success endpoint. With no control arm and such a small, high-dropout sample, this is uncontrolled, exploratory evidence rather than a definitive efficacy trial.

Reported efficacy

Number of Patients Achieving the CD34+ Hematopoietic Stem Cell (HSC) Mobilization Target of ≧2.5×1000000 Cells/kg (1 week): Number of Patients Achieving the CD34+ Hematopoietic Stem Cell (HSC) Mobilization Target of ≧2.5×1000000 Cells/kg (1 week): TG-0054 (3.14 mg/kg) 7/7 | TG-0054 (3.14 mg/kg)+G-CSF 5/5 (not_applicable)

Result source: NCT01458288

Motixafortide

Marketed by Ayrmid Ltd. and partners

Approved in Multiple Myelomapeptide
Partial signal

NCT03246529 · Phase 3 · active, not recruiting

GENESIS was a randomized, double-blind, placebo-controlled Phase 3 trial in patients with multiple myeloma. In Part 2, 122 patients were randomized 2:1 to motixafortide (n=80) or placebo (n=42), each given with filgrastim. The single primary endpoint was the proportion of patients who collected at least 6 x 10^6 CD34+ cells/kg in up to 2 aphereses, read by the central laboratory. The FDA label reports 67.5% with motixafortide and 9.5% with placebo (p < 0.0001), so the primary endpoint was met. The endpoint is a stem-cell collection count, which is a surrogate for transplant outcomes. Source: the APHEXDA US label, section 14, and the ClinicalTrials.gov posted results.

Next expected readout: December 2026 · NCT07101445 (registry estimate)

Reported efficacy

Percentage of Subjects Mobilizing ≥6 × 10^6 CD34+ Cells/kg With up to 2 Apheresis Sessions (From first day of study treatment (G-CSF) until day of second apheresis which was planned to occur on Day 6): Proportion of patients who collected at least 6 x 10^6 CD34+ cells/kg in up to 2 aphereses (central laboratory), randomized Part 2, motixafortide + filgrastim (n=80) vs placebo + filgrastim (n=42): 67.5% vs 9.5%, adjusted difference 56.8%, p < 0.0001 (stratified Cochran-Mantel-Haenszel; APHEXDA US label, section 14). CT.gov posted results for the same randomized groups give 70.0% vs 14.3%, p < 0.0001 (Cochran-Mantel-Haenszel). (met)

Result source: NCT03246529

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBurixafor (TG-0054)Motixafortide
PFS, median—Not reported—Trial running · NCT03246529
OS, median—Not reported—Trial running · NCT03246529
ORR—Not reported—Trial running · NCT03246529
VGPR or better—Not reported—Trial running · NCT03246529
MRD negativity—Not reported—Trial running · NCT03246529

PFS, median

Burixafor (TG-0054)
—Not reported
Motixafortide
—Trial running · NCT03246529

OS, median

Burixafor (TG-0054)
—Not reported
Motixafortide
—Trial running · NCT03246529

ORR

Burixafor (TG-0054)
—Not reported
Motixafortide
—Trial running · NCT03246529

VGPR or better

Burixafor (TG-0054)
—Not reported
Motixafortide
—Trial running · NCT03246529

MRD negativity

Burixafor (TG-0054)
—Not reported
Motixafortide
—Trial running · NCT03246529
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. Burixafor (TG-0054): 4 of 5 rows · Motixafortide: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricBurixafor (TG-0054)Motixafortide
CD34 Target Achievement
event count · % of participants
No placebo or comparator arm
100% (n=7) @ 1wk*3.14 mg/kga,b,c,d
NCT01458288 · Phase 2 · monotherapy · converted to % from 7 participants as posted
show 1 more dose
100% (n=5) @ 1wk*3.14 mg/kg + G-CSF
NCT01458288 · Phase 2 · combination · converted to % from 5 participants as posted
91.7% (n=24) @ 0.29wk*a,b,c,d
NCT02639559 · Phase 2 · converted to % from 22 Participants as posted
show 1 more dose
100% (n=9) @ 0.29wk*
NCT02639559 · Phase 2 · converted to % from 9 Participants as posted
Dropout rate
76.9%3.14 mg/kge
NCT01018979 · Phase 2 · monotherapy
show 3 more results
42.9%2.24 mg/kg
NCT01018979 · Phase 2 · monotherapy
—3.14 mg/kg IV
NCT01458288 · Phase 2 · monotherapy
—3.14 mg/kg
NCT02104427 · Phase 2 · registry result, not featured evidence · combination
—BL-8040 + G-CSF (Part 2)f
NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3
show 3 more results
0%BL-8040 + G-CSF Part 1
NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3
7.5%BL-8040 + G-CSF Part 2
NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3
4%
NCT02639559 · Phase 2
Discontinued due to AEs
—3.14 mg/kge
NCT01018979 · Phase 2 · monotherapy
show 3 more results
—2.24 mg/kg
NCT01018979 · Phase 2 · monotherapy
—3.14 mg/kg IV
NCT01458288 · Phase 2 · monotherapy
—3.14 mg/kg
NCT02104427 · Phase 2 · registry result, not featured evidence · combination
—BL-8040 + G-CSF (Part 2)f
NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3
show 3 more results
0%BL-8040 + G-CSF Part 1
NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3
2.5%BL-8040 + G-CSF Part 2
NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3
—
NCT02639559 · Phase 2
Serious AEs
50%3.14 mg/kge
NCT01018979 · Phase 2 · monotherapy
show 3 more results
28.6%2.24 mg/kg
NCT01018979 · Phase 2 · monotherapy
0%3.14 mg/kg IV
NCT01458288 · Phase 2 · monotherapy
0%3.14 mg/kg
NCT02104427 · Phase 2 · registry result, not featured evidence · combination
8.8%BL-8040 + G-CSF (Part 2)f
NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3
show 3 more results
8.3%BL-8040 + G-CSF Part 1
NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3
—BL-8040 + G-CSF Part 2
NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3
0%
NCT02639559 · Phase 2
Most frequent reported AEs
3.14 mg/kge
leukocytosis 16.7%
cardiac disorders-other:qt prolong at 24hr-36hr after infusion 8.3%
diarrhea 8.3%
NCT01018979 · Phase 2 · monotherapy
show 3 more results
2.24 mg/kg
dizziness 28.6%
leukocytosis 28.6%
abdominal pain 14.3%
NCT01018979 · Phase 2 · monotherapy
3.14 mg/kg IV
diarrhoea 33.3%
neuropathy peripheral 33.3%
abdominal pain 16.7%
NCT01458288 · Phase 2 · monotherapy
3.14 mg/kg
diarrhoea 8.3%
dry mouth 8.3%
hypokalaemia 8.3%
NCT02104427 · Phase 2 · registry result, not featured evidence · combination
f
injection site pain 50% (placebo 4.8%)
pruritus 32.5% (placebo 0%)
injection site erythema 27.5% (placebo 0%)
NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3
show 2 more results
injection site pain 75% (placebo 4.8%)
pruritus 66.7% (placebo 0%)
injection site pruritus 41.7% (placebo 0%)
NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3
lymphocyte count increased 88%
platelet count decreased 88%
allergic reaction 80%
NCT02639559 · Phase 2

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bOne study enrolled healthy volunteers and the other enrolled patients.
  3. cPopulation context differs: registered conditions differ.
  4. dAssessment timepoints differ: 0.29 weeks versus 1 weeks.
  5. ePopulation comparability has not been reviewed for these studies.
  6. fPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Burixafor (TG-0054)

Leukapheresis Sessions 2 count @ 1wk3.14 mg/kg
event count · count
No placebo or comparator arm
NCT01458288 · Phase 2 · monotherapy
show 1 more result
1.4 count @ 1wk3.14 mg/kg + G-CSF
NCT01458288 · Phase 2 · combination
CD34 2e6 Mobilization 89.5%
event count · % of participants
No placebo or comparator arm
NCT05561751 · Phase 2 · sponsor-reported, not registry data

Motixafortide

CD34 6e6 Mobilization up to 2 Apheresis 70% (n=80) vs 14.3% (n=42) placebo @ 0.857wk
absolute value · percentage points
Central Lab
NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3
CD34 2e6 Mobilization 1 Apheresis 87.5% (n=80) vs 47.6% (n=42) placebo @ 0.714wk
absolute value · percentage points
Central Lab
NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3
CD34 6e6 Mobilization 1 Apheresis 67.5% (n=80) vs 4.8% (n=42) placebo @ 0.714wk
absolute value · percentage points
Central Lab
NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3
Time to Neutrophil Engraftment Median 0.39 vs 0.39 placebo months
time to event · months
NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3 · converted to months from 12 days as posted
show 1 more result
0.39 vs 0.39 placebo months*
NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3 · converted to months from 12 days as posted
Time to Platelet Engraftment Median 0.56 vs 0.56 placebo months
time to event · months
NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3 · converted to months from 17 days as posted
show 1 more result
0.59 vs 0.56 placebo months*
NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3 · converted to months from 18 days as posted
Graft Durability 92.2% (n=77) vs 91.9% (n=37) placebo @ 14.3wk
absolute value · percentage points
NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3
show 3 more results
80.5% (n=77) vs 83.8% (n=37) placebo @ 26wk
NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3
83.1% (n=77) vs 81.1% (n=37) placebo @ 39wk
NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3
81.8% (n=77) vs 81.1% (n=37) placebo @ 52wk
NCT03246529 · Phase 3 · combination · Multiple Myeloma · phase 3

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Burixafor (TG-0054)'s landscape · Motixafortide's landscape